Darin Lippoldt Sells 6,279 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Darin Lippoldt sold 6,279 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $75.04, for a total transaction of $471,176.16. Following the sale, the insider now owns 19,436 shares in the company, valued at $1,458,477.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Darin Lippoldt also recently made the following trade(s):

  • On Wednesday, November 15th, Darin Lippoldt sold 9,900 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $73.05, for a total transaction of $723,195.00.

Neurocrine Biosciences, Inc. (NBIX) traded up $1.25 during trading on Friday, hitting $73.75. 873,530 shares of the stock were exchanged, compared to its average volume of 1,101,527. Neurocrine Biosciences, Inc. has a 12-month low of $37.35 and a 12-month high of $75.98. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.36. The business had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter last year, the firm earned ($0.43) earnings per share. equities analysts forecast that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the company. First Trust Advisors LP increased its holdings in shares of Neurocrine Biosciences by 29.0% in the 3rd quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock worth $47,963,000 after buying an additional 176,136 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Neurocrine Biosciences by 49.7% during the 2nd quarter. Canada Pension Plan Investment Board now owns 24,700 shares of the company’s stock worth $1,136,000 after purchasing an additional 8,200 shares during the period. Davidson Kempner Capital Management LP purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth about $3,639,000. Artisan Partners Limited Partnership purchased a new position in shares of Neurocrine Biosciences during the 2nd quarter worth about $15,981,000. Finally, State Street Corp boosted its stake in shares of Neurocrine Biosciences by 5.1% during the 2nd quarter. State Street Corp now owns 2,710,196 shares of the company’s stock worth $124,666,000 after purchasing an additional 131,141 shares during the period.

Several analysts have recently commented on NBIX shares. Piper Jaffray Companies set a $68.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Thursday, August 24th. ValuEngine upgraded shares of Neurocrine Biosciences from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Oppenheimer reiterated a “buy” rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a report on Thursday, September 7th. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price target on shares of Neurocrine Biosciences in a report on Sunday, September 17th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $66.00 price target on shares of Neurocrine Biosciences in a report on Thursday, September 21st. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. Neurocrine Biosciences presently has a consensus rating of “Buy” and an average target price of $78.88.

TRADEMARK VIOLATION WARNING: This news story was first posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://weekherald.com/2017/12/09/darin-lippoldt-sells-6279-shares-of-neurocrine-biosciences-inc-nbix-stock.html.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply